Instructions for Amlodipine Aspartate Tablets
Release time:
2020-07-31
Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015
Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use
[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:
Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax
:
More information
Spike Cable Enters South American Market
Recently, a batch of 2100-pair communication cables produced by Peak Cable Company for Venezuelan customers have been completed and will be shipped in cabinets. This is the company's first export business in the South American market. In recent years, under the general trend of "light in and copper out" in the domestic market, Jianfeng Cable Company has taken the initiative to open up foreign markets that still use copper-core communication cables. While making use of its own production advantages to actively cooperate with domestic industry and trade enterprises to carry out foreign trade processing of communication cables, it has made great efforts to expand its own export business through foreign trade platforms and participation in exhibitions. Since the beginning of this year, the cable company has overcome the adverse effects of the new coronary pneumonia epidemic, actively looking for foreign customers for business negotiations, and won orders from Vietnamese customers shortly after the resumption of work. It is understood that in all the export business of cable companies this year, self-operated export business has accounted for about half, and the export direction is mainly Southeast Asia. The successful completion of the Venezuelan customer orders for the future further development of Colombia, Argentina, Peru, Chile and other South American countries to lay a good foundation. (Hu Longgang, Huang Yuan)
2020
11-12
Daye peak "war epidemic" work was commended by Hubei Province, Huangshi City
Recently, Daye Peak Cement Company won the commendation of Hubei Provincial Federation of Industry and Commerce, Hubei General Chamber of Commerce, Huangshi City Federation of Industry and Commerce, Huangshi City Chamber of Commerce, Huangshi City People's Government Poverty Alleviation and Development Office and other relevant units for its outstanding achievements in the prevention and control of the new coronary pneumonia epidemic. Since the beginning of this year, in the face of the new coronary pneumonia epidemic, Daye Peak has fully implemented the important instructions of the municipal government on the prevention and control of the new coronary pneumonia epidemic and the decision-making and deployment of poverty alleviation, obeying the overall situation, not only donating money to the Daye Municipal People's Government for the first time to help prevent and control the epidemic, but also actively do a good job in the prevention and control of the internal epidemic, and to resume production, and earnestly implement the municipal party committee and municipal government on the response to the impact of the new coronary pneumonia epidemic to carry out "two help two help" and "three get one stable" work requirements, paired to help the surrounding rural part of the population has not been lifted out of poverty, to help poor areas to solve the problem of agricultural and sideline products sales, for the city's decisive fight against poverty to contribute. (Yang Huiping, Zhang Qingyu)
2020
11-12
Liu Haiping, Vice Mayor of Pu'er, went to Yunnan Jianfeng for investigation
On the morning of November 3, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of the municipal government, and responsible persons of relevant departments went to Yunnan Jianfeng cement Company for investigation and discussion with Zhou Jiping, general manager of Yunnan Jianfeng, and Fang Xuhua, deputy general manager, on such topics as improving the business environment of Pu'er City and the difficulties encountered in the production and operation of enterprises. During the exchange, Zhou Jiping reported on the production and operation of the company this year, as well as the impact of the new coronary pneumonia epidemic on the market and the difficulties encountered in the production and operation process. Liu Haiping fully affirmed the efforts and achievements made since the resumption of work and production in Yunnan Peak, and said that a good business environment is very important for economic development and enhancing the vitality of enterprises. The functional departments of Pu'er government at all levels will continue to optimize various tasks, improve work efficiency, and provide services and guarantees for the development of enterprises. Liu Haiping hopes that Yunnan Jianfeng, as a key enterprise and "benchmark enterprise" in Pu'er City, will play a pioneering and exemplary role and jointly promote the construction of the business environment in Pu'er City. (qi jianmei)
2020
11-12
On the afternoon of November 10, the Party committee of the group company held an enlarged meeting to learn the spirit of the Fifth Plenary Session of the 19th CPC Central Committee and make arrangements for the next step of study, publicity and implementation. At the meeting, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, together with all members of the Party committee, members of the management team of the group company, heads of functional departments and some party members, studied the communique of the Fifth Plenary Session of the 19th CPC Central Committee and interpreted the spiritual points of the plenary session. Jiang Xiaomeng pointed out that the Fifth Plenary Session of the 19th Central Committee of the Communist Party of China, held in Beijing from October 26 to 29, is a very important meeting held at an important historical moment when the victory of building a moderately prosperous society in an all-round way is in sight and the new journey of building a modern socialist country in an all-round way is about to begin. It fully embodies the foresight of the Party Central Committee with Comrade Xi Jinping as the core in planning the future and the historical responsibility of carrying forward the past, and profoundly points out the guidelines, objectives, tasks, and strategic measures for China's development in the coming period. It is of great and far-reaching significance to mobilize and encourage the whole Party and the people of the whole country to continue to seize the important strategic opportunity period and promote the comprehensive construction of a socialist modern country. In response to the goals and some hot issues raised in the plenary communiqué, such as how to achieve the 2035 long-term goal, the key goals of economic and social development during the "14th Five-Year Plan" period, why the emphasis is on adhering to the party's overall leadership and strengthening the centralized and unified leadership of the party Central Committee. The main risks and challenges facing economic development in the next five years, how to achieve scientific and technological self-reliance, promote innovation, how to understand the construction, jiang Xiaomeng quoted the answers given by the leaders of relevant central ministries and commissions at the press conference of the plenary session. Jiang Xiaomeng emphasized that China's current development environment is facing profound and complex changes, and there are new developments and changes in opportunities and challenges. The guiding ideology and principles of economic and social development during the "14th Five-Year Plan" period proposed by the plenary session, and the economy during the "14th Five-Year Plan" period The main goals of social development will have a direct impact on the future development of our enterprises. Party organizations at all levels and all employees at the peak must study and study carefully, find the entry point and direction of work, make every effort to complete the annual work goals, and make preparations for the next year. The person in charge of the party organization of the company's overseas enterprises participated in the study through the video conference system. (this newspaper reporter)
2020
11-12
Zhou Zhou, executive vice governor of Qiandongnan Prefecture, sent a message to Huang Ping Jianfeng: fully promote the normalization of production and marketing to make new contributions to Huang Ping's overall well-off society. On October 27, Zhou Zhou, executive vice governor of Qiandongnan Prefecture, Guizhou Province, Yang Zhi, head of Huangping County, and relevant officials of the state and county governments went to Guizhou Huangping Jianfeng Cement Company to investigate and understand the project construction and production situation, and hope that the enterprises will develop as soon and promote regional economic development. Hu Hongwei, general manager of Huang Ping Jianfeng, and other members of the management team made a report on the overall work since the construction of the project started, and accompanied Zhou Zhou Zhou and his party to visit the production line site. In the central control room, Hu Hongwei to Zhou Zhou
2020
11-03
Zhang Xinyu, Vice Mayor of Jinhua City, hopes that Jianfeng Pharmaceutical will aim at cutting-edge science and technology to speed up the development of enterprises. On the afternoon of October 16, Zhang Xinyu, Vice Mayor of Jinhua City, and his party went to the construction site of Jianfeng Pharmaceutical's internationalization project of producing 2 billion pieces of solid preparations annually to conduct research. Accompanied by Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and Shen Quan, deputy general manager of the pharmaceutical company, Zhang Xinyu and his entourage visited the preparation workshop under construction and affirmed the civilized construction and safety management of the site. Huang Jinlong introduced the basic situation of the project to Zhang Xinyu and his party. Knowing that Jianfeng Pharmaceutical has introduced world-class production equipment and advanced technology to build a high-end preparation manufacturing platform in order to achieve industrial upgrading, Zhang Xinyu expressed his appreciation and encouraged Jianfeng Pharmaceutical to gain a foothold in China, aim at the world's cutting-edge technology, and accelerate the pace of enterprise development. Continuously enhance the overall competitiveness of the enterprise. (Wang xuesheng/Wen Zhou hengbin/photo)
2020
11-03
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page